Skip to main content

Table 1 Patient characteristics

From: Parathyroid imaging with 18F-fluorocholine PET/CT as a first-line imaging modality in primary hyperparathyroidism: a retrospective cohort study

 

All patients

n = 271

Operated patients

n = 139

Patients treated with calcimimetics

n = 48

Patients without active treatment

n = 84

Age (years)

62 ± 12 (29–86)*

60 ± 11 (29–81)*

67 ± 11 (43–86)*

64 ± 11 (31–83)*

Sex (n)

 Female

205 (76%)

107 (77%)

34 (71%)

64 (76%)

 Male

66 (24%)

32 (23%)

14 (29%)

20 (24%)

PTH (pmol/L) (normal range 1.3–6.8 pmol/L)

16.1 ± 11.3 (2.4–121.9)*

n = 271

17.9 ± 13.5 (4.5–121.9)*

n = 139

16.7 ± 11.2 (4.3–57.1)*

n = 48

12.6 ± 5.1 (2.4–26.0)*

n = 84

Serum calcium (mmol/L) (normal range 2.10–2.50 mmol/L)

2.66 ± 0.21 (2.11–3.86)*

n = 271

2.72 ± 0.21 (2.11–3.86)*

n = 139

2.67 ± 0.20 (2.14–3.14)*

n = 48

2.56 ± 0.18 (2.16–2.96)*

n = 84

Serum phosphate (mmol/L) (normal range 0.7–1.4 mmol/L)

0.9 ± 0.2 (0.3–1.5)*

n = 223

0.8 ± 0.2 (0.3–1.2)*

n = 120

0.9 ± 0.2 (0.6–1.2)*

n = 38

0.9 ± 0.2 (0.5–1.5)*

n = 65

24-h urinary calcium (mmol/24 h) (normal range 2.5–7.5 mmol/24 h)

7.2 ± 4.0 (0.1–18.5)*

n = 198

8.8 ± 3.9 (0.1–18.5)*

n = 99

6.4 ± 3.5 (0.7–14.3)*

n = 37

5.6 ± 3.8 (0.5–17.5)*

n = 62

SUVmax (early images)

6.1 ± 2.9 (1.5–20.5)*

n = 197

6.3 ± 2.7 (1.5–12.7)*

n = 127

5.9 ± 2.6 (2.7–12.5)*

n = 36

5.7 ± 3.8 (2.1–20.5)*

n = 34

SUVmax (late images)

4.9 ± 2.2 (1.3–13.7)*

n = 203

5.0 ± 2.2 (1.3–12.0)*

n = 132

4.7 ± 2.4 (1.6–13.7)*

n = 37

4.4 ± 2.0 (1.8–9.9)*

n = 34

  1. PTH parathyroid hormone, SUVmax maximum standardized uptake value
  2. *mean ± SD (range)